Aphaia Pharma Initiates Second Phase 2 Trial of Oral Candidate in Obesity
- Second Phase 2 trial builds on encouraging initial results from a prior Phase 2 study
- Aphaia’s formulation activates gastrointestinal nutrient-sensing signaling pathways to modify the course of obesity and associated metabolic diseases